Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin in patients with Right Heart Failure (Dapa-RHF)
2022-000420-38Phase 2Active
- Sponsor
- Universitätsmedizin Göttingen
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Right heart dysfunction (RHF) comparing Dapagliflozin + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Change in serum NT-proBNP level from baseline to end of treatment (Delta-NT-proBNP). Started May 2023; status: active.
02
Drugs
dapagliflozin
03
Conditions
Right heart dysfunction (RHF)
Beyond the preview
Go deeper on 2022-000420-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000420-38.